EICHORCondition: Asthma · Sponsor: AstraZeneca
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Research Site | Mesa, Arizona, United States | — |
| Research Site | Huntington Beach, California, United States | — |
| Research Site | La Mesa, California, United States | — |
| Research Site | Laguna Niguel, California, United States | — |
| Research Site | Lancaster, California, United States | — |
| Research Site | Long Beach, California, United States | — |
| Research Site | San Jose, California, United States | — |
| Research Site | New Haven, Connecticut, United States | — |
| Research Site | DeBary, Florida, United States | — |
| Research Site | Jacksonville, Florida, United States | — |
| Research Site | Jensen Beach, Florida, United States | — |
| Research Site | Largo, Florida, United States | — |
+ 184 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06529419